https://www.selleckchem.com/pr....oducts/diphenyleneio
As a result, the best treatment recommendations for females in these fields are currently guided by outcomes evaluated primarily in males. Conclusions Female enrollment in device clinical trials for coronary revascularization and heart failure has lagged, leaving uncertainty in making benefit/risk assessments of device therapy. The predictors of female nonparticipation in clinical trials can inform a comprehensive strategy to facilitate and enrich the enrollment of females in cardiovascular device trials. This i
Like
Comment
Share
